The purpose of this study was to evaluate possible associations between systemic immune dysregulation (activated CD8 D epression, stress, and anxiety have been associated with immune dysregulation in a variety of chronic diseases (1-3), although whether they play a causative role in immune dysregulation or are a symptom of it in a given disease is not always clear (4). In HIV-infected adults and youth, symptoms of depression and stress are associated with impaired cellular immunity (lower natural killer [NK] cell count and function [2, [5] [6] [7] and higher cytotoxic CD8 ϩ T-lymphocyte counts [5, 8] ), increased risk of disease progression, and higher systemic HIV morbidity and mortality (1, 6, (8) (9) (10) (11) (12) . Mechanistically, depression and stress may induce cellular immune dysregulation (13) through direct effects on serotonin and norepinephrine cellular receptors and coreceptors, thereby altering the biochemical input to the hypothalamic-pituitary axis and glucocorticoid system (9, 14). However, studies have failed to directly link depression-associated serum cortisol release with clinical HIV disease progression as measured by development of CDC-defined AIDS and mortality (9). In addition, treatment with adequate antiretroviral therapy (ART) reverses immune dysregulation in HIV infection, but ART does not significantly affect depression-HIV-associated morbidity and mortality (15, 16). Thus, the mechanisms underlying the relationship between psychiatric illness and HIV immunology remain to be elucidated.
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We propose an alternative potential causal pathway model to explain the association of depression, stress, anxiety, and immune dysregulation in HIV neuropathogenesis, based on the known neuropathophysiology of HIV-associated neurocognitive disorders (HAND). HIV enters the central nervous system (CNS) soon after primary infection through infected monocytes and lymphocytes that migrate across the blood-brain barrier (17) (18) (19) (20) . Once in the CNS, infected monocytes differentiate into perivascular macrophages that continue to support low-level viral replication, infect neighboring astrocytes and microglia (19) , recruit more CD8 ϩ T lymphocytes to the CNS (21) , and release soluble cytokines/chemokines, resulting in local astrocyte activation and inflammation. Astrocyte activation reduces inherent astrocytic neuroprotective functions (19) , leading to increased blood-brain barrier permeability (22) and therefore increased (and probably ongoing) transmigration of infected monocytes and CD8 ϩ T lymphocytes (23) . In addition, activated monocytes/macrophages, astrocytes, and CD8 ϩ T lymphocytes increase parenchymal concentrations of glutamate, other excitatory neurotransmitters, and secreted neurotoxins and induce oxidative and nitrosative stress, leading to neuronal damage (18, 22) . The resultant synaptic loss and dendritic simplification seen on neuropathology are clinically associated with HAND and morbidity/mortality in HIV (24) . Lower peripheral NK cell count and functional activity appear to worsen this CNS pathology in rapid-progression simian immunodeficiency virus (SIV)-infected macaque models of HIV; the same models demonstrate that higher counts and function in acute infection predict less severe SIV CNS lesions, suggesting a role of NK cells in neuroprotection (25, 26) .
We hypothesize that neuropsychiatric symptoms in HIV stem at least partially from a neuropathophysiology similar to that of HAND as described above and are therefore significantly impacted by the important primary roles of activated CD8 ϩ T lymphocytes and NK cells in HIV neuropathogenesis (Fig. 1) . Clinically, HAND and depression may be related: HIV-infected adults with depression perform significantly worse than those without depression on neurocognitive testing in some studies (27) but not in all (28) . There are far fewer data regarding the relationship between anxiety, HAND, and mortality. Immunologically, emerging data suggest that cell-mediated immune activation and neuroinflammation in HIV infection may lead to serotonin depletion, thereby contributing to symptoms of depression and anxiety (27, 28) .
NK cell counts/function and activated CD8 ϩ CD38 ϩ T lymphocytes have previously been described in a cohort of adolescents with horizontally (behaviorally) acquired HIV infection (29) (30) (31) where depression and anxiety were prevalent. However, there is a paucity of literature on the neuropathogenesis of HIV in these youth. This study therefore aimed to evaluate the potential relationship over time between markers of immune dysregulation (NK cell count/function and activated CD8 ϩ CD38 ϩ T cells) and symptoms of depression and anxiety in youth with horizontally acquired HIV infection. This study is thus the first step in a larger agenda to investigate whether central and peripheral immune dysregulation in HIV infection mediates both the neurocognitive and neuropsychiatric manifestations of HIV, via structural and metabolic changes associated with HIV neuropathogenesis (2, 4, (17) (18) (19) 32) .
MATERIALS AND METHODS
Study design and participants. We performed a secondary analysis of prospectively collected data from the NIH/NICHD-funded Reaching for Excellence in Adolescent Care and Health (REACH) project of the Adolescent Medicine HIV/AIDS Research Network (AMHARN). Characteristics of the cohort, recruitment, detailed eligibility criteria, and study design are reported elsewhere (33) . Briefly, the REACH project was a longitudinal, observational study of HIV-infected and high-risk uninfected adolescents aged 12 to 18 years old at enrollment, recruited from 15 different centers across 13 U.S. cities, evaluating biomedical and behavioral features of HIV infection between March 1996 and November 2000 (n ϭ 578). To be eligible for enrollment, HIV-infected adolescents (diagnosed with a positive enzyme-linked immunosorbent assay that was confirmed by Western blotting prior to enrollment in the REACH study) must have acquired their infection via sexual activity or needle-sharing behavior (2) . Inclusion criteria for the present secondary analysis included all REACH subjects who were HIV infected (n ϭ 365) and had a minimum of two study visits separated by 12 months, with laboratory measurements documented (n ϭ 326). Adolescents who seroconverted during the study time period (n ϭ 3), those who were pregnant or within 3 months postpartum at a given study visit, or those for whom sex or race data were not available were excluded. The total final number of subjects included in this analysis was 323.
Data collection and laboratory measures. (i) Original data collection. Original data collection for the REACH project had been approved by the institutional review boards (IRBs) of each of the participating study sites. All subjects provided written consent to participate in the REACH study, and parental permission was obtained when required. Data were originally collected via face-to-face interviews, audio computer-assisted self-administered interview (ACASI), medical chart abstraction, and laboratory analysis of blood and urine samples. The deidentified REACH database was obtained for this secondary analysis following permission from the NICHD Adolescent Medicine Trials Network for HIV/AIDS Interventions Program Director and IRB approval at the Children's Hospital of Philadelphia. The present analysis was limited to the first 36 months of study participation.
(ii) Predictor variables. All predictor variables were measured every 6 months during the REACH study time frame. Basic flow cytometry was performed in whole blood at individual study sites in AIDS Clinical Trials Group (ACTG)-certified laboratories every 3 months using standard protocols to measure CD3 Ϫ CD56 ϩ CD16 ϩ NK cells (2 NK cell, thereby adjusting for differences in the percentages of NK cells (2) . This NK cell functional activity was measured in heparinized blood at a central immunology laboratory (laboratory of S. D. Douglas), using a modification of standard techniques. NK activity was calculated as (mean sample activity Ϫ mean spontaneous release) ϫ 100. The results were expressed as percent cytotoxicity (2) . Lytic units per 10 7 PBMCs were calculated according to standard methods (34) . Lytic units per NK cell were calculated based on lytic units per PBMC and the absolute NK cell number in the effector PBMC population, as determined by automated flow cytometry at the time of the NK cell assay.
Expanded flow cytometry was performed in whole blood at a central immunology laboratory (laboratory of S. D. Douglas) every 3 months on samples shipped from each clinical site to measure CD8 ϩ CD38 ϩ T lymphocytes; specimens were processed within 30 h of collection. Sample viability was greater than 97% (2) . Cell phenotypes were determined using standard 3-color flow cytometry. The absolute number of activated T lymphocytes was calculated similarly to the calculation for the NK cells as described above, based on the percentage of CD8 ϩ CD38 ϩ T lymphocytes, the CBC, and the DLC.
(iii) Outcome variables. Depressive symptoms were measured using the Center for Epidemiologic Studies depression scale (CES-D) (35) every 3 months for 3 years and then every 6 months for the remainder of the REACH study time frame. The CES-D is a 20-item self-report scale using the patient's preceding week as the reference frame for questions evaluating symptoms of depression, which results in a score of 0 to 60. It was developed at the National Institute of Mental Health to measure depressive symptoms among adults in community epidemiologic surveys (35) . It has been validated in adolescents (36) and has good internal consistency (Cronbach's ␣ ϭ 0.88; range ϭ 0 to 1) (37). Anxiety was measured using 2 subscales of the Revised Children's Manifest Anxiety Scale (RCMAS) (38) every 6 months for the REACH study duration. The RCMAS is a validated 37-item self-report instrument used to assess the level and nature of anxiety in children and adolescents over the preceding week. The Physiological Anxiety subscale of the RCMAS contains 10 yes/no items, and the Worry/Oversensitivity subscale contains 11 yes/no items. The RCMAS has good internal consistency (Cronbach's ␣ ϭ 0.69 for the Physiological Anxiety subscale and 0.84 for the Worry/Oversensitivity subscale) (39) .
(iv) Covariates. Plasma viral load (VL) was initially quantified with a nucleic acid sequence-based amplification (NASBA) assay with a lower limit of detection of 400 copies/ml. Later in the REACH study, a secondgeneration isothermal nucleic acid sequence-based amplification method (NucliSens) with a lower limit of detection of 80 copies/ml replaced the NASBA (2, 40) . Missing values of VL were assumed to be 1 copy/ml below the limit of detection of a given assay if the test was documented as performed but no value of VL was recorded. Pregnancy was considered positive if any of the following was documented: if a urine or serum lab test was positive at a given visit, if study staff made specific notes of pregnancy, or if an estimated date of confinement was documented after a given visit. Anyone with all of these data either negative or missing was assumed not to be pregnant. The postpartum period was defined as the first nonpregnant visit immediately after a given subject was documented to be pregnant. Psychiatric hospitalization was defined as any admission for psychiatric reasons or for drug or alcohol detoxification. A positive psychiatric history was counted as present if an individual had any inpatient or outpatient psychiatric care since his or her last interval visit. Highly active ART (HAART) was defined as being on 3 or more ART drugs or on 2 ART drugs if one was a combination drug. CNS penetration effectiveness (CPE) scores were defined in the standard manner (41); amprenavir was assumed to have the same CPE as it is prodrug fosamprenavir (CPE ϭ 2), and adefovir was assumed to have the same CPE as the chemically similar tenofovir (CPE ϭ 1). No CPE score was assigned to dapsone. CPE was coded as 0 if not on ART. CNS opportunistic infection (OI) was defined as any history of CNS toxoplasmosis, encephalitis, cytomegalovirus (CMV), retinitis, primary lymphoma of the brain, progressive multifocal leukoencephalopathy (PML), HIV-E, cryptococcal meningitis, or HIV dementia. If these data were not documented (n ϭ 14), CNS OIs were assumed to not be present. The presence of sexually transmitted infections (STI) was defined as positive laboratory documentation of current hepatitis B virus antibodies, hepatitis C virus antibodies, syphilis (positive direct fluorescent-antibody assay [DFA] or serology), herpes simplex virus (HSV) culture, Haemophilus ducreyi culture, Neisseria gonorrhoeae culture, or Chlamydia trachomatis culture.
Data analysis and statistical methods. Data were analyzed using Stata version 12.1 (2011; StataCorp, College Station, TX). The REACH data set contained a checkerboard of missing data among predictor variables, outcome variables, and time-varying covariates. Our approach to dealing with missing data was to impute missing data using chained equations with 10 imputations (42-44) for all predictors, all outcomes, and five time-varying covariates of interest (CD4 ϩ T-lymphocyte count, viral load, ART regimen, illicit drug use, and recent psychiatric care) prior to the creation of any univariable or multivariable regression models. Subjects were censored after they dropped out of the study. Because convergence issues did not allow for imputation of all missing data for all time points, we chose to limit the analysis to outcomes measured at consecutive visits at 12, 18, 24, 30, and 36 months, a point after which the follow-up dropped off considerably. For nonimputed time-varying covariates, recent values were carried back for missing entries, at times for more than one missing data point. For the last visit included in the analysis, recent values were carried forward for missing entries. Imputation was implemented in Stata's program "ice." Sensitivity analyses with different follow-up times and methods of imputation, 12-month change versus static level of predictor variables, and to test the assumption of lack of differential missingness were performed, details of which can be found in the Appendix.
(i) Descriptive analysis. The distributions and univariable associations of outcomes, predictors, and covariates were first examined to assess the nature of their underlying data structure. The predictor variables (CD8 ϩ CD38 ϩ activated T-lymphocyte count, CD3 Ϫ CD16 ϩ CD56 ϩ NK cell count, NK lytic units per NK cell, and NK lytic units per PBMC) demonstrated skewed distributions with long right-hand tails. They were therefore transformed with a natural log function to approximate normality, and the transformed data were used in subsequent analyses, as in prior reports (2, 30, 45) . The three outcome variables (depression, anxiety measured by worry symptoms, and anxiety measured by physiologic signs, as measured by the CES-D and RCMAS scales) had wide enough ranges to be considered continuous and were individually examined with each predictor variable and covariate described above.
(ii) Univariable linear regression. In an effort to reduce the potential covariate set prior to multivariable analysis, several initial approaches to modeling were used to objectively exclude unimportant potential covariates from further consideration. To allow for the presumptive biologic forward inference of immune function on symptoms of depression and anxiety, predictor variables and time-varying covariates were examined as measured 12 months before each outcome variable. Correlations of various combinations of covariates were examined to assess for possible colinearity. Linear regression models examining each individual predictor and each covariate with each outcome variable were constructed using generalized estimating equations (GEE) to account for the multiple study visits of each subject (46) . At this stage, only those covariates that indicated potential predictive value or importance as either covariates or confounders (using a conservative P value of 0.20 as a screening cut point) or those judged to be important based on biologic plausibility were considered further in multivariable analysis.
(iii) Multivariable linear regression. Linear regression models examining each individual predictor variable with each outcome variable and all covariates of interest determined as described above were constructed using GEE. Each model was constructed beginning with each outcome and predictor of interest, all covariates significant on univariable analysis, and other covariates important in the causal pathway (age, viral load, and CD4 ϩ T-lymphocyte count). Covariates that did not retain significance in the adjusted model (P Ͼ 0.05) were then eliminated one at a time. The predictor of interest, gender, and race were retained a priori in all models. Confounding variables, defined as covariates whose elimination resulted in important changes in the effect size of the predictor variable, were retained. As described above, predictors and time-varying covariates were considered lagged and time specific in the regression. Interaction terms examining predictor variables interacting with sex and race were examined in all models.
RESULTS
Baseline demographic characteristics at enrollment of the 323 subjects are summarized in Table 1 . Briefly, the median age was 17.6 (interquartile range [IQR], 16.8 to 18.3; range, 13.1 to 19.3), with 89% of participants over the age of 16 years. Similar to the REACH cohort as a whole, 75% of subjects were female, and 74% were African American (47) . Although 76% of subjects had carried a known HIV diagnosis for less than 2 years prior to baseline, 17% did qualify for a baseline diagnosis of AIDS, defined as a CD4
ϩ T-lymphocyte count of Ͻ200 cells/l, a CD4 ϩ T-lymphocyte percentage of total lymphocytes of Ͻ14%, or presence of an AIDS-defining illness (48) . Thirty-three percent had a VL of Ն10,000 copies/ml. Forty-one percent were ART naive, and 23% were receiving highly active ART (HAART). The mean duration of follow-up for the REACH subcohort meeting the eligibility criteria for this analysis was 3.2 years.
The results of univariable analysis of each predictor and each covariate with each outcome variable are presented in Table 2 . Consistent with the study hypothesis, higher measures of NK cell functional activity (in lytic units per PBMC) were significantly associated with lower physiologic and worry anxiety symptoms 12 months later. Similarly, higher measures of NK cell functional activity in lytic units per NK cell were associated with lower physiologic anxiety symptoms 12 months later. No immune marker of interest was associated with depression. All covariates with values in bold in Table 2 were carried forward in adjusted multivariable models as potential confounders.
Multivariable models adjusted for all relevant covariates maintained the association noted on univariable analysis between higher NK cell functional activity (lytic units per PBMC) and lower symptoms of physiologic anxiety, although the magnitude of effect was small. Specifically, physiologic anxiety symptoms decreased by 0.192 for every natural log increase in NK lytic units per PBMC (P ϭ 0.019) ( Table 3 ). In addition, while on univariable analysis no immune marker of interest was associated with symptoms of depression, higher activated CD8 ϩ CD38 ϩ T-lymphocyte counts were significantly associated with lower symptoms of depression on adjusted analysis, contrary to the study hypotheses (Table 3 ). This magnitude of effect was again small: depression symptoms decreased by 0.954 for every natural log increase in CD8 ϩ CD38 ϩ T lymphocytes (P ϭ 0.038). The remainder of the adjusted models did not demonstrate significant associations between other immune markers of interest and symptoms of depression or anxiety (see Tables A1 to A4) .
Sensitivity analyses examining outcomes 6 months and 24 months following each predictor variable did not demonstrate any important difference in model results. Specifically, at 24 months the relationship between higher NK lytic units per PBMC and lower physiologic anxiety symptoms was preserved (P ϭ 0.031). Subsequent exploratory models examining the change of predictor variables over the 12 months prior to measuring each outcome of interest resulted in only one statistically significant model (NK cell count and depression, beta ϭ 0.095 and P ϭ 0.05). The remainder of the change models were not significant, including those that were significant on the primary analysis of modeling e HAART was defined as being on 3 or more ART drugs or on 2 ART drugs if one was a combination drug. f Central nervous system penetration-effectiveness (CPE) scores were defined in the standard manner (48); amprenavir was assumed to have the same CPE as its prodrug fosamprenavir (CPE ϭ 2), and adefovir was assumed to have the same CPE as the chemically similar tenofovir (CPE ϭ 1). No CPE score was assigned to dapsone. CPE was coded as 0 if the subject was not on ART. g CNS opportunistic infection (OI) was defined as any history of CNS toxoplasmosis, encephalitis, CMV, retinitis, primary lymphoma of the brain, PML, HIV-E, cryptococcal meningitis, or HIV dementia. If these data were not documented (n ϭ 14), CNS OIs were assumed not to be present. h The presence of sexually transmitted infections (STI) was defined as positive laboratory documentation of current hepatitis B antibodies, hepatitis C antibodies, syphilis (positive DFA or serology), HSV culture, H. ducreyi culture, N. gonorrhoeae culture, or C. trachomatis culture.
predictor levels (CD8 ϩ CD38 ϩ T lymphocytes and depression, beta ϭ Ϫ0.094 and P ϭ 0.896; lytic NK units per PBMC and physiologic anxiety, beta ϭ Ϫ0.005 and P ϭ 0.957). Next, exploratory models created to test the assumption of a lack of differential missing data did not demonstrate significantly different results than our primary analysis. Specifically, significant relationships were preserved (CD8 ϩ /CD38 ϩ T lymphocytes and depression, beta ϭ Ϫ0.731 and P ϭ 0.081; lytic NK units per PBMC and physiologic anxiety, beta ϭ Ϫ0.181 and P ϭ 0.045), and models previously not significant did not become so. Finally, an analysis examining a composite NK measure identifying either low NK count or low NK functional activity in each individual at a given time point was not a significant predictor of symptoms of depression or anxiety.
DISCUSSION
In summary, we observed that higher measures of NK cell functional activity were associated with fewer physiologic anxiety symptoms 12 months later and that higher counts of activated CD8 ϩ CD38 ϩ T lymphocytes were associated with fewer depressive symptoms 12 months later. While the directional nature of the relationship between the NK measures and anxiety was as expected, it was of very low magnitude and is therefore of unclear clinical significance. The RCMAS worry and physiologic anxiety subscales each have mean normative values based on age, sex, and race; in 13-to 19-year-old healthy nonanxious youth, the mean worry subscale ranges from 2.6 to 5.9 (scale, 0 to 11), and the mean physiologic symptom subscale ranges from 2.4 to 5.5 (scale, 0 to 10). In the present study, the mean worry score from the 12-to 36-month study visit decreased by 0.5 (4.3 to 3.8; two-sided t test, P Ͻ 0.001) across the entire cohort. Similarly, the mean physiologic anxiety score from the 12-to 36-month visits decreased by 0.5 (3.4 to 2.9; P Ͻ 0.001). It is possible that the effect of immune dysregulation on these anxiety symptoms was therefore attenuated by healthy-user bias in the study. Specifically, youth enrolled in the REACH cohort were well linked into medical and psychiatric care over several years with providers they trusted; the overall improvement in mental health symptoms may have been reflective of the nurturing nature of these care relationships, as opposed to an improvement attributable solely to their NK cell measures.
Conversely, the hypothesized relationship between activated CD8 ϩ CD38 ϩ T-lymphocyte counts and symptoms of depression was not demonstrated. The mean CES-D score across the cohort decreased by a total of 1.2 (P Ͻ 0.001) between the 12-and 36-month study visits, again suggesting that the nurturing study environment of the REACH cohort may have had independent beneficial effects on the mental health of the enrolled youth, obscuring any change in depressive symptoms attributable to immune dysregulation. In addition, in the context of such an environment, if an adolescent became medically ill from their HIV infection (which would likely result in an elevated CD8 ϩ CD38 ϩ T-lym- a Values in bold were carried forward in adjusted multivariable models as potential confounders. b Age (n ϭ 323), viral load (n ϭ 323), duration of infection (n ϭ 312), current CD4 count (n ϭ 323), CDC disease progression stage (n ϭ 318), and comorbid sexually transmitted infection (n ϭ 318) were also examined but were not significant in any of these models.
phocyte count), they may have received closer attention, thus mitigating the development of resultant depression symptoms. Similar reasons may account for the fact that relationships between other immune markers and neuropsychiatric outcomes were not significant in other models. These NK-specific data are internally consistent with prior limited, cross-sectional data from the REACH study. Douglas et al. demonstrated an association between decreased NK lytic activity per PBMC and increased anxiety symptoms (worry, not physiology) (n ϭ 501, 329 of whom were HIV infected) (2); there was no cross-sectional association between depression symptoms and NK count. In another cross-sectional study of the REACH cohort, Douglas et al. demonstrated differential NK count/function between men and women and different races (n ϭ 412, 280 of whom were HIV infected) (30) . In the current study, we therefore included gender and race a priori in all regression models.
For the REACH cohort as a whole, NK cells were defined as CD3 Ϫ CD16 ϩ CD56 ϩ cells, which are the most traditional subtype of NK cells and likely comprise Ͼ95% of circulating NK cells in healthy individuals (49) . However, there is a distinct and much less common subtype of CD3 Ϫ CD16 ϩ CD56 Ϫ NK cells (which are significantly less cytotoxic than the traditional subtype) that after the REACH study took place were found to be expanded in HIV-infected adults in association with high HIV RNA viral loads. Some have hypothesized that NK cell impairment in HIV infection is due to the higher frequencies of this dysfunctional CD56 Ϫ NK cell subset (50) . Unfortunately, because the flow instrumentation at the time of the REACH study did not have the capability to regate previously run samples, we were unable to look for the presence of this subpopulation directly. However, if this subpopulation was significantly present in these REACH youth and contributing to the total lytic activity of the sample, this would falsely elevate the lytic units per NK cell, as all NK cells may not be accounted for, while lytic units per PBMC would still remain an accurate measurement of overall sample lytic activity. These differences may be involved in why lytic units per PBMC were a significant predictor of anxiety, but lytic units per NK were not, and why NK cell count was not a significant predictor of any of the neuropsychiatric outcomes.
The current study is the first to examine the relationships between activated CD8 ϩ CD38 ϩ T lymphocytes (31) and neuropsychiatric symptoms, which have not been previously described for the REACH cohort. While the results were contrary to those expected, this could easily be an artifact of the retrospective study design reflecting factors unaccounted for in these models as intermediaries between activated CD8 ϩ CD38 ϩ T lymphocytes and depression. For example, if systemic disease was worsening as evidenced by an increase in activated T lymphocytes, youth may have been followed more closely in their medical home, with more aggressive counseling regarding mental health. A larger, prospective study is needed to better fully assess this relationship.
Interestingly, in this model, female sex was found to be protective against depression (Tables 2 and 3) in both univariable and multivariable models, which is contrary to most prior observations (8) . These findings could reflect a healthy-user bias, as the REACH cohort was strongly weighted toward minority females receiving regular medical care with close relationships with their caregivers, likely resulting in better overall health, better control of HIV, and fewer comorbidities. In addition, of note, HAART was associated with decreased depression and anxiety on univariable analysis and in the significant multivariable model examining CD8 ϩ CD38 ϩ T-lymphocyte count and depression. This finding is internally consistent with the proposed causal pathway model, as HAART should reduce systemic immune activation and would thus protect against neuropsychiatric complications of HIV.
There were several limitations to our study, including the inherent inability to control for unrecognized confounders in a retrospective nonrandomized study. Specifically, there may be different, unknown causes of varied immune biology other than HIV and the covariates examined. In addition, the REACH cohort was a largely systemically healthy but viremic group of young people with a relatively short duration of infection. This population may have different immune-neuropsychiatric relationships than an older cohort with longer duration of infection or than a virologically suppressed cohort on ART. Therefore, results may not be broadly generalizable. Third, recall bias and/or response (social desirability) bias may have affected survey portions of this study. However, this bias should be nondifferential, and survey questions were limited to symptoms in the last week to minimize recall bias. Response bias was minimized by asking sensitive questions regarding substance use and depression/anxiety with ACASI. Fourth, a healthy-user bias may be present, as described above. Finally, data were missing in this cohort due to skipped visits, transient incarcerations, and pregnancy; however, such missingness is expected to be nondifferentially distributed, and the analysis plan with multiple imputation and repeated-measures modeling would be anticipated to attenuate these effects. A sensitivity Tables A1 to A4. analysis supported the assumption of the lack of differential missingness. In summary, our study objectively evaluated whether depression and anxiety symptoms are the result, not the cause, of immune dysregulation in HIV infection by using a longitudinal regression model. Our results offer preliminary data on a possible relationship between higher NK cell functional activity and subsequent fewer physiologic symptoms of anxiety and therefore open the door for further investigation into the causal pathway of these and related neuropsychiatric disorders. The hypothesized relationship of elevated activated CD8 ϩ
CD38
ϩ T lymphocytes with increased depressive symptoms was not confirmed. If the above-proposed mechanistic rationale is correct, then neuropsychiatric therapy needs to be directed toward targeting the neuropathophysiology and immune dysregulation of HIV infection. Further investigation into the prevalence of formal neurocognitive deficits in this population and their interrelationships with anxiety and immune dysregulation is warranted.
APPENDIX
Final multivariable linear regression models of all predictor/outcome pairings are detailed in Tables A1 to A4. A sensitivity analysis was performed to examine predictor variables and time-varying covariates as measured both 6 and 24 months before each outcome variable, in comparison to the primary analysis that assessed these measures 12 months before each outcome. Similar to the primary analysis, we performed multiple imputation using chained equations with 10 imputations for all predictors, all outcomes, and five covariates of interest (CD4 ϩ T-lymphocyte count, viral load, ART regimen, illicit drug use, and recent psychiatric care) prior to the creation of any regression models. Subjects were again censored after they A second sensitivity analysis was performed to examine if change of a predictor variable over the 12 months prior to an outcome may predict outcomes differently than the primary analysis assessing the level of predictor variable. Multiple imputation methods were performed in a method identical to that in the primary analysis, substituting change for level predictor variables, prior to the creation of any regression models.
Finally, a third sensitivity analysis was performed to test the assumption of lack of differential missingness of data. In the primary analysis, one of the most frequently missing variables was physiologic anxiety. Therefore, for this assessment we eliminated all data points that were missing a physiologic anxiety value from the nonimputed data and then reimputed all other key variables in a method identical to that in the primary analysis, prior to the creation of new regression models.
All imputation described above was implemented in Stata's program "ice," as in the primary analysis. 
